Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study
Anna Cardellino, Julia R. Correll, Mona Martin, Boris Gorsh, Sandhya Sapra, Rakesh Popat · 2023
Read Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study by Anna Cardellino, Julia R. Correll, Mona Martin, Boris Gorsh, Sandhya Sapra, Rakesh Popat (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10748584.txt.
Description
Anna Cardellino and co-authors interview patients about life on a myeloma drug inside a clinical trial, in a study published in 2023. Belantamab mafodotin treats relapsed or refractory multiple myeloma, a blood cancer marked by bone pain and fatigue. The DREAMM-2 trial embedded telephone interviews at the fourth treatment cycle and at the end of treatment.
Across 142 interviews with 111 patients, common complaints included nerve symptoms, fatigue, and bone or joint pain. Patients who responded to the drug reported easing symptoms. Eye problems seen during the trial were at or near resolution by the final interviews. Both responders and others worried most about changes to daily life and routines, and participants were generally satisfied with the treatment.
Catalog record
| CREATOR | Anna Cardellino, Julia R. Correll, Mona Martin, Boris Gorsh, Sandhya Sapra, Rakesh Popat |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |